Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial
Abstract Eriocitrin (eriodictyol 7‐O‐β‐rutinoside), a citrus flavonoid from lemon juice and peel, reduces hyperglycemia and improves diabetes‐related biomarkers in prediabetes patients. Eriocitrin is first metabolized by gut microbiota, producing energy for gut cells and short chain fatty acids that...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Food Science & Nutrition |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/fsn3.3654 |
| _version_ | 1797633814661431296 |
|---|---|
| author | Fernanda M. M. Ramos Carolina B. Ribeiro Thais B. Cesar Dragan Milenkovic Lucélia Cabral Melline F. Noronha Katia Sivieri |
| author_facet | Fernanda M. M. Ramos Carolina B. Ribeiro Thais B. Cesar Dragan Milenkovic Lucélia Cabral Melline F. Noronha Katia Sivieri |
| author_sort | Fernanda M. M. Ramos |
| collection | DOAJ |
| description | Abstract Eriocitrin (eriodictyol 7‐O‐β‐rutinoside), a citrus flavonoid from lemon juice and peel, reduces hyperglycemia and improves diabetes‐related biomarkers in prediabetes patients. Eriocitrin is first metabolized by gut microbiota, producing energy for gut cells and short chain fatty acids that play a relevant role in glycemic control. The aim of this study was to assess the effect of Eriomin®, a nutraceutical composed of 70% eriocitrin, 5% hesperidin, and 4% naringin, on the microbiota of prediabetic patients. Patients were randomly divided into two groups and received unlabeled capsules of Eriomin® (200 mg/day) or placebo during 12 weeks. After treatment with the nutraceutical, it was a 6% decrease of hyperglycemia and 22% increase of GLP‐1 blood levels of (p < .05). The profile of intestinal microorganisms, obtained by 16S rRNA sequencing of the patients' feces extract, showed changes in microbiota composition, such as lower growth of Firmicutes and less abundance of the Lachnospiraceae family. The family Ruminococcaceae increased and Blautia genus reduced with Eriomin® supplementation. In additional, Blautia was positively correlated with hyperglycemia reduction. In conclusion, the nutraceutical Eriomin® moderately reduced the growth of microorganisms associated with intestinal dysbiosis and increased the abundance of beneficial bacteria. Changes promoted mainly by the flavonoid eriocitrin in the microbiota were related to a lower glycemic level and increased production of GLP‐1 in patients with prediabetes. |
| first_indexed | 2024-03-11T11:58:54Z |
| format | Article |
| id | doaj.art-92d84102b10b4955a018060069f4684e |
| institution | Directory Open Access Journal |
| issn | 2048-7177 |
| language | English |
| last_indexed | 2024-03-11T11:58:54Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Food Science & Nutrition |
| spelling | doaj.art-92d84102b10b4955a018060069f4684e2023-11-08T09:39:18ZengWileyFood Science & Nutrition2048-71772023-11-0111117283729510.1002/fsn3.3654Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trialFernanda M. M. Ramos0Carolina B. Ribeiro1Thais B. Cesar2Dragan Milenkovic3Lucélia Cabral4Melline F. Noronha5Katia Sivieri6Graduate Program in Food, Nutrition and Food Engineering Sao Paulo State University (UNESP) Araraquara BrazilGraduate Program in Food, Nutrition and Food Engineering Sao Paulo State University (UNESP) Araraquara BrazilGraduate Program in Food, Nutrition and Food Engineering Sao Paulo State University (UNESP) Araraquara BrazilDepartment of Nutrition University of California Davis Davis California USAInstitute of Biosciences, Depart of General and Applied Biology São Paulo State University (UNESP) Rio Claro BrazilResearch Informatics Core, Research Resource Center University of Illinois at Chicago Chicago Illinois USAGraduate Program in Food, Nutrition and Food Engineering Sao Paulo State University (UNESP) Araraquara BrazilAbstract Eriocitrin (eriodictyol 7‐O‐β‐rutinoside), a citrus flavonoid from lemon juice and peel, reduces hyperglycemia and improves diabetes‐related biomarkers in prediabetes patients. Eriocitrin is first metabolized by gut microbiota, producing energy for gut cells and short chain fatty acids that play a relevant role in glycemic control. The aim of this study was to assess the effect of Eriomin®, a nutraceutical composed of 70% eriocitrin, 5% hesperidin, and 4% naringin, on the microbiota of prediabetic patients. Patients were randomly divided into two groups and received unlabeled capsules of Eriomin® (200 mg/day) or placebo during 12 weeks. After treatment with the nutraceutical, it was a 6% decrease of hyperglycemia and 22% increase of GLP‐1 blood levels of (p < .05). The profile of intestinal microorganisms, obtained by 16S rRNA sequencing of the patients' feces extract, showed changes in microbiota composition, such as lower growth of Firmicutes and less abundance of the Lachnospiraceae family. The family Ruminococcaceae increased and Blautia genus reduced with Eriomin® supplementation. In additional, Blautia was positively correlated with hyperglycemia reduction. In conclusion, the nutraceutical Eriomin® moderately reduced the growth of microorganisms associated with intestinal dysbiosis and increased the abundance of beneficial bacteria. Changes promoted mainly by the flavonoid eriocitrin in the microbiota were related to a lower glycemic level and increased production of GLP‐1 in patients with prediabetes.https://doi.org/10.1002/fsn3.3654clinical trialeriocitrin nutraceuticalEriomin®intestinal dysbiosislemon flavonoidmicrobiota (16S rRNA) |
| spellingShingle | Fernanda M. M. Ramos Carolina B. Ribeiro Thais B. Cesar Dragan Milenkovic Lucélia Cabral Melline F. Noronha Katia Sivieri Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial Food Science & Nutrition clinical trial eriocitrin nutraceutical Eriomin® intestinal dysbiosis lemon flavonoid microbiota (16S rRNA) |
| title | Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial |
| title_full | Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial |
| title_fullStr | Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial |
| title_full_unstemmed | Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial |
| title_short | Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double‐blind randomized controlled trial |
| title_sort | lemon flavonoids nutraceutical eriomin r attenuates prediabetes intestinal dysbiosis a double blind randomized controlled trial |
| topic | clinical trial eriocitrin nutraceutical Eriomin® intestinal dysbiosis lemon flavonoid microbiota (16S rRNA) |
| url | https://doi.org/10.1002/fsn3.3654 |
| work_keys_str_mv | AT fernandammramos lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT carolinabribeiro lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT thaisbcesar lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT draganmilenkovic lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT luceliacabral lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT mellinefnoronha lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial AT katiasivieri lemonflavonoidsnutraceuticaleriominattenuatesprediabetesintestinaldysbiosisadoubleblindrandomizedcontrolledtrial |